X-Feed Billboard (International)
The newsboard processes news from the NASDAQ Nordic portfolio company GlobeNewswire, which provides investors with company-relevant information. This relates in particular to events that may be relevant to the listing of companies or tradable financial instruments.
GlobNewswire (formerly PrimeNewswire) specializes in public relations solutions and digital media services. This feed adds another important source of information for investors to the popular X-Billboard portfolio.
24-month follow-up data from randomized Phase I part of the Phase I/II trial of TG4050
in resected locally advanced head and neck cancer selected for rapid oral presentation
at ASCO on June 1st, 2025
TG4050: Updated randomized Phase I data to be presented in Rapid Oral Presentation at ASCO 2025
Strasbourg, France, April 24, 2025, 8:00 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available.
Document d'Enregistrement Universel 2024
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 10, 2025, under number D.25-0243.
2024 Full-year results and business update
Strasbourg (France), January 21, 2025, 5:45 PM CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by AllInvest Securities, this event will take place on February 4, 2025, in Paris.
Strasbourg (France), January 14, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces its financial reporting dates for 2025:
Transgene will present median 24-month follow up data from patients
enrolled in the Phase I trial evaluating the individualized cancer vaccine TG4050
in the adjuvant treatment of head and neck cancer
TRANSGENE (Paris: TNG) today announced that it has made available to the public and filed with the Autorité des marchés financiers its half-year financial report as of June 30, 2024.
2024 Half-Year Results and Business Update
2024 Half Year Financial Report
Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment
BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors.
These data, published in The Journal for ImmunoTherapy of Cancer (JITC), demonstrate that TG6050 induces tumor regression and profound remodeling of the tumor microenvironment
Ce communiqué ne peut être publié, transmis ou diffusé ou distribué, directement ou indirectement, aux États-Unis, au Canada, en Australie ou au Japon.
Ce communiqué ne peut être publié, transmis ou diffusé ou distribué, directement ou indirectement, aux États-Unis, au Canada, en Australie ou au Japon.
Strasbourg, France, and Lund, Sweden, July 22, 2024, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, will jointly present a poster on initial clinical results from the Phase I part of the ongoing randomized Phase I/IIa trial of BT-001 at the European Society of Medical Oncology (ESMO) Annual Meeting. ESMO will take place in Barcelona, Spain, from September 13 to 17, 2024.
Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of June 30, 2024, the following resources were managed through the liquidity account:
The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.
RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.
Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.
On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.